JP2020502198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502198A5 JP2020502198A5 JP2019533195A JP2019533195A JP2020502198A5 JP 2020502198 A5 JP2020502198 A5 JP 2020502198A5 JP 2019533195 A JP2019533195 A JP 2019533195A JP 2019533195 A JP2019533195 A JP 2019533195A JP 2020502198 A5 JP2020502198 A5 JP 2020502198A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- seq
- substitution
- composition according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims 1
- 102220346328 c.82G>T Human genes 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102200017779 rs10132601 Human genes 0.000 claims 1
- 102220232822 rs1085307660 Human genes 0.000 claims 1
- 102220139548 rs61735306 Human genes 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023016174A JP7750887B2 (ja) | 2016-12-20 | 2023-02-06 | 癌免疫療法のための併用療法での多重特異性抗体 |
Applications Claiming Priority (29)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1621782.0 | 2016-12-20 | ||
| GBGB1621782.0A GB201621782D0 (en) | 2016-12-20 | 2016-12-20 | Antibodies and immunocytokines PD-L1 specific antibodies and PD-L1 specific immunocytokines |
| GB1702339.1 | 2017-02-13 | ||
| GBGB1702339.1A GB201702339D0 (en) | 2017-02-13 | 2017-02-13 | Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines |
| GBGB1702338.3A GB201702338D0 (en) | 2017-02-13 | 2017-02-13 | Antibodies and immunocytokines PD-L1 specific antibodies and specific immunocytokines |
| GB1702338.3 | 2017-02-13 | ||
| GB1703071.9 | 2017-02-24 | ||
| GBGB1703071.9A GB201703071D0 (en) | 2017-02-24 | 2017-02-24 | Antibodies |
| US15/480,525 US10604576B2 (en) | 2016-06-20 | 2017-04-06 | Antibodies and immunocytokines |
| US15/480,525 | 2017-04-06 | ||
| TW106120563A TW201803905A (zh) | 2016-06-20 | 2017-06-20 | 用於免疫腫瘤學之多重專一性抗體 |
| PCT/GB2017/051795 WO2017220989A1 (en) | 2016-06-20 | 2017-06-20 | Anti-pd-l1 and il-2 cytokines |
| GB1709818.7 | 2017-06-20 | ||
| GBGB1709818.7A GB201709818D0 (en) | 2017-06-20 | 2017-06-20 | Antibodies |
| TW106120562A TWI784957B (zh) | 2016-06-20 | 2017-06-20 | 免疫細胞介素 |
| TW106120564 | 2017-06-20 | ||
| TW106120564A TWI640536B (zh) | 2016-06-20 | 2017-06-20 | 抗體 |
| TW106120562 | 2017-06-20 | ||
| PCT/GB2017/051794 WO2017220988A1 (en) | 2016-06-20 | 2017-06-20 | Multispecific antibodies for immuno-oncology |
| TW106120563 | 2017-06-20 | ||
| PCT/GB2017/051796 WO2017220990A1 (en) | 2016-06-20 | 2017-06-20 | Anti-pd-l1 antibodies |
| GBPCT/GB2017/051795 | 2017-06-20 | ||
| GBPCT/GB2017/051794 | 2017-06-20 | ||
| GBPCT/GB2017/051796 | 2017-06-20 | ||
| TW106126908A TWI760352B (zh) | 2016-08-09 | 2017-08-09 | 抗ｉｃｏｓ抗體 |
| GBPCT/GB2017/052352 | 2017-08-09 | ||
| TW106126908 | 2017-08-09 | ||
| PCT/GB2017/052352 WO2018029474A2 (en) | 2016-08-09 | 2017-08-09 | Anti-icos antibodies |
| PCT/GB2017/053826 WO2018115859A1 (en) | 2016-12-20 | 2017-12-19 | Multispecific antibody with combination therapy for immuno-oncology |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023016174A Division JP7750887B2 (ja) | 2016-12-20 | 2023-02-06 | 癌免疫療法のための併用療法での多重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502198A JP2020502198A (ja) | 2020-01-23 |
| JP2020502198A5 true JP2020502198A5 (enExample) | 2021-01-28 |
| JP7290568B2 JP7290568B2 (ja) | 2023-06-13 |
Family
ID=61192960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533195A Active JP7290568B2 (ja) | 2016-12-20 | 2017-12-19 | 癌免疫療法のための併用療法での多重特異性抗体 |
| JP2023016174A Active JP7750887B2 (ja) | 2016-12-20 | 2023-02-06 | 癌免疫療法のための併用療法での多重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023016174A Active JP7750887B2 (ja) | 2016-12-20 | 2023-02-06 | 癌免疫療法のための併用療法での多重特異性抗体 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20200190191A1 (enExample) |
| EP (1) | EP3559041A1 (enExample) |
| JP (2) | JP7290568B2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116640214A (zh) * | 2016-08-09 | 2023-08-25 | 科马布有限公司 | 分离抗体及其应用 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) * | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| CA3171597A1 (en) * | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| CN115698075A (zh) * | 2020-04-14 | 2023-02-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 涉及抗icos和抗pd1抗体，任选地进一步涉及抗tim3抗体的癌症的组合治疗 |
| WO2022243378A1 (en) * | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| WO2023057534A1 (en) * | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
| EP4525991A1 (en) * | 2022-05-18 | 2025-03-26 | Kymab Limited | Uses of anti-icos antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2775761C (en) * | 2009-09-30 | 2018-08-28 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| RS60614B1 (sr) * | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| CN116640214A (zh) * | 2016-08-09 | 2023-08-25 | 科马布有限公司 | 分离抗体及其应用 |
| EP3728314A1 (en) * | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
-
2017
- 2017-12-19 US US16/471,161 patent/US20200190191A1/en not_active Abandoned
- 2017-12-19 EP EP17840565.0A patent/EP3559041A1/en active Pending
- 2017-12-19 JP JP2019533195A patent/JP7290568B2/ja active Active
-
2023
- 2023-02-06 JP JP2023016174A patent/JP7750887B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502198A5 (enExample) | ||
| JP2023055904A5 (enExample) | ||
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| JP2015514110A5 (enExample) | ||
| JP2013542194A5 (enExample) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| NZ723369A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
| JP2012523417A5 (enExample) | ||
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| NZ631405A (en) | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| JP2020536109A5 (enExample) | ||
| NZ590343A (en) | Compositions monovalent for cd28 binding and methods of use | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| ME02798B (me) | Protutijela protiv dkk-1" | |
| AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. | |
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
| PH12014500089A1 (en) | Antibodies that bind to ox40 and their uses | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| RU2010145177A (ru) | Лекарственное средство для лечения рака печени |